MELD ESAS Evolution: Assessment of the Symptomatic Burden of Patients With Advanced Chronic Liver Disease

NCT06181474 | Completed DMC

• 1 other identifier: ULSM_131/CES/JAS
• Study Type: observational
• Target: 44
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this observational study is to understand if there is a correlation between the evolution of MELD-Na and symptomatic burden of patients with advanced chronic liver disease. All patients with chronic liver disease will be invited to participate in the study. Patients will be followed prospectively with assessment of their MELD-Na score and symptom burden, according to the Edmonton Symptom Assessment System scale.

Conditions

Palliative Care; End Stage Liver DIsease

Keywords

Hepatology; End Stage Liver Disease; Palliative Care

Outcome Measures

Primary Outcomes (1)

• MELD ESAS

  Evaluate and correlate the evolution of MELD-Na and ESAS on advanced chronic liver disease.

  1 year

Interventions

ESAS OTHER

Observation of symptoms

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All patients with chronic liver disease followed in the Matosinhos Local Health Unit after their first episode of decompensation or are diagnosed with hepatocellular carcinoma in stage C or D of the Barcelona Liver Clinic Cancer will be invited to participate in the study.

You may qualify if:

• All patients with chronic liver disease

You may not qualify if:

• do not sign consent to participate
• patients under 18 years of age
• patients who present a recurrent degree of encephalopathy, according to the West-Haven scale, equal or greater than 2

Sponsors & Collaborators

• Unidade Local de Saúde de Matosinhos, EPE: lead

Study Sites (1)

Hugo Miguel Oliveira

Matosinhos Municipality, Portugal

Location

Related Publications (1)

• Oliveira HM, Ribeiro F, Lopes G, Frias E, Andrade F, Guiomar V, Eiras E, Rego F, Nunes R. Symptom burden in end-stage liver disease: a prospective cohort study of the symptoms experienced by patients and the role of palliative care. Therap Adv Gastroenterol. 2025 Jul 13;18:17562848251353624. doi: 10.1177/17562848251353624. eCollection 2025.

  PMID: 40661221 DERIVED

MeSH Terms

Conditions

End Stage Liver Disease

Condition Hierarchy (Ancestors)

Liver Failure; Hepatic Insufficiency; Liver Diseases; Digestive System Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 1 Year
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: December 12, 2023
• First Posted: December 26, 2023
• Study Start: January 1, 2024
• Primary Completion: December 31, 2024
• Study Completion: January 25, 2025
• Last Updated: May 4, 2025

Record last verified: 2025-03

Data Sharing

• IPD Sharing: Will not share

Locations

PT (1)